Similar companies
Income Statement (USD)
| Q1 '24 | QoQ | |
|---|---|---|
| Operating expense | 9.3M | 27.3% |
| Net Income | -9.9M | 26.6% |
| EBITDA | -9.3M | 0% |
Balance Sheet (USD)
| Q1 '24 | QoQ | |
|---|---|---|
| Total Assets | 21M | 14.8% |
| Total Liabilities | 39M | 2.7% |
| Shares Outstanding | 19M | 95.8% |
Cash Flow (USD)
| Q1 '24 | QoQ |
|---|
EPS
Financial Highlights for Aslan Pharmaceuticals in Q1 '24
Operating Expenses for this period were 9.3M, showing a -27.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -9.9M, showing a 26.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -9.3M, showing a 0% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
